We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 342

Universities abroad experiment with no-fee licensing to drive biotech partnerships

  • Shook Hardy & Bacon LLP
  • -
  • Australia, Canada, European Union, United Kingdom, USA
  • -
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies

Putative class alleges pharma statements about new drug violated securities laws

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

Aveo Pharmaceuticals, Inc. and several of its executives have been targeted in a securities class action filed in a federal court in Massachusetts

NASDAQ Biotechnology Index surpasses all-time high in 1Q13

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe

Congress advances pharma supply chain and animal-drug user-fee laws

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The House Energy and Commerce Subcommittee on Health has reportedly approved draft legislation that would change the existing lot-level

Biotech receives $32.5 million for cancer research

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

Celator Pharmaceuticals, Inc., a Princeton, New Jersey-based company that develops cancer therapies, has raised $32.5 million in the final closing of

French company prevails in dispute with FDA over drug-classification ruling

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 3 2012

A federal court in the District of Columbia has determined that the Food and Drug Administration (FDA) erred when it classified a combination drug-device product as primarily a drug, thus subjecting its French manufacturer to more burdensome regulatory requirements

Cleave Biosciences secures $10 million to support cancer therapies

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 18 2013

Cancer drug developer, Cleave Biosciences Inc., has secured $10 million in Series A financing from new investor New Enterprise Associates (NEA

$13.6 billion deal to merge rival genetic-sequencing machine companies

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 18 2013

Thermo Fisher Scientific has reportedly agreed to purchase Life Technologies Corp. for $13.6 billion in a deal expected to close in early 2014

News Bytes - May 16, 2013

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The National Institutes of Health (NIH) Office of Biotechnology Activities proposes revising the "NIH Guidelines for Research Involving Recombinant

U.S. intervenes in False Claims Act suit against biotech company

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 4 2013

The U.S. government has intervened in part of a False Claims Act (FCA) lawsuit against Agave BioSystems, a biotechnology-based small business with

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy